311 related articles for article (PubMed ID: 7756673)
1. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia.
Yu J; Papavasiliou V; Rhim J; Goltzman D; Kremer R
Anticancer Drugs; 1995 Feb; 6(1):101-8. PubMed ID: 7756673
[TBL] [Abstract][Full Text] [Related]
2. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer.
El Abdaimi K; Papavasiliou V; Rabbani SA; Rhim JS; Goltzman D; Kremer R
Cancer Res; 1999 Jul; 59(14):3325-8. PubMed ID: 10416587
[TBL] [Abstract][Full Text] [Related]
3. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
4. Effects of 1,25(OH)2D3, EB1089, and analog V on PTHrP production, PTHrP mRNA expression and cell growth in SCC 2/88.
Kunakornsawat S; Rosol TJ; Capen CC; Middleton RP; Hannah SS; Inpanbutr N
Anticancer Res; 2001; 21(5):3355-63. PubMed ID: 11848494
[TBL] [Abstract][Full Text] [Related]
5. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
Haq M; Kremer R; Goltzman D; Rabbani SA
J Clin Invest; 1993 Jun; 91(6):2416-22. PubMed ID: 8514854
[TBL] [Abstract][Full Text] [Related]
6. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
7. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089.
Zhang X; Jiang F; Li P; Li C; Ma Q; Nicosia SV; Bai W
Clin Cancer Res; 2005 Jan; 11(1):323-8. PubMed ID: 15671562
[TBL] [Abstract][Full Text] [Related]
8. Amphiregulin is a vitamin D3 target gene in squamous cell and breast carcinoma.
Akutsu N; Bastien Y; Lin R; Mader S; White JH
Biochem Biophys Res Commun; 2001 Mar; 281(4):1051-6. PubMed ID: 11237771
[TBL] [Abstract][Full Text] [Related]
9. Regulation of parathyroid hormone-related protein production by a squamous carcinoma cell line in vitro.
Merryman JI; Capen CC; McCauley LK; Werkmeister JR; Suter MM; Rosol TJ
Lab Invest; 1993 Sep; 69(3):347-54. PubMed ID: 8377475
[TBL] [Abstract][Full Text] [Related]
10. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.
Akutsu N; Lin R; Bastien Y; Bestawros A; Enepekides DJ; Black MJ; White JH
Mol Endocrinol; 2001 Jul; 15(7):1127-39. PubMed ID: 11435613
[TBL] [Abstract][Full Text] [Related]
11. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy.
Aklilu F; Park M; Goltzman D; Rabbani SA
Cancer Res; 1997 Oct; 57(20):4517-22. PubMed ID: 9377563
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
14. Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo.
Vegesna V; O'Kelly J; Said J; Uskokovic M; Binderup L; Koeffle HP
Anticancer Res; 2003; 23(1A):283-9. PubMed ID: 12680225
[TBL] [Abstract][Full Text] [Related]
15. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.
Boehm MF; Fitzgerald P; Zou A; Elgort MG; Bischoff ED; Mere L; Mais DE; Bissonnette RP; Heyman RA; Nadzan AM; Reichman M; Allegretto EA
Chem Biol; 1999 May; 6(5):265-75. PubMed ID: 10322128
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of parathyroid hormone-like peptide expression and secretion in a keratinocyte model of tumor progression.
Henderson J; Sebag M; Rhim J; Goltzman D; Kremer R
Cancer Res; 1991 Dec; 51(24):6521-8. PubMed ID: 1742725
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
Lokeshwar BL; Schwartz GG; Selzer MG; Burnstein KL; Zhuang SH; Block NL; Binderup L
Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study.
Ghous Z; Akhter J; Pourgholami MH; Morris DL
Anticancer Res; 2008; 28(6A):3757-61. PubMed ID: 19189661
[TBL] [Abstract][Full Text] [Related]
19. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
Barreto AM; Schwartz GG; Woodruff R; Cramer SD
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
[TBL] [Abstract][Full Text] [Related]
20. A group of deltanoids (vitamin D analogs) regulate cell growth and proliferation in small cell carcinoma cell lines.
Güzey M; DeLuca HF
Res Commun Mol Pathol Pharmacol; 1997 Oct; 98(1):3-18. PubMed ID: 9434311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
